Aurinia Pharmaceuticals Inc (AUPH) is a publicly traded Healthcare sector company. As of May 19, 2026, AUPH trades at $15.59 with a market cap of $1.97B and a P/E ratio of 6.86. AUPH moved +0.32% today. Year to date, AUPH is +1.63%; over the trailing twelve months it is +90.48%. Its 52-week range spans $6.55 to $16.88. Analyst consensus is buy with an average price target of $16.00. Rallies surfaces AUPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aurinia Pharmaceuticals Inc (AUPH) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. AUPH moved +0.32% today. Analyst consensus is buy.
| Metric | Value |
|---|---|
| Price | $15.59 |
| Market Cap | $1.97B |
| P/E Ratio | 6.86 |
| EPS | $2.26 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.88 |
| 52-Week Low | $6.55 |
| Volume | 170.35K |
| Avg Volume | 0 |
| Revenue (TTM) | $298.30M |
| Net Income | $298.21M |
| Gross Margin | 89.74% |
4 analysts cover AUPH: 0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.00.